Clinical Trial Update: Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated Itacitinib for bronchiolitis obliterans syndrome after donor hematopoietic cell transplant and has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bronchiolitis Obliterans | Phase 1 | Status: TERMINATED